Disc Medicine Statistics
Total Valuation
Disc Medicine has a market cap or net worth of $3.00 billion. The enterprise value is $2.40 billion.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Disc Medicine has 34.77 million shares outstanding. The number of shares has increased by 29.27% in one year.
| Current Share Class | 34.77M |
| Shares Outstanding | 34.77M |
| Shares Change (YoY) | +29.27% |
| Shares Change (QoQ) | +5.10% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 96.80% |
| Float | 29.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.78 |
| P/TBV Ratio | 4.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.11, with a Debt / Equity ratio of 0.05.
| Current Ratio | 32.11 |
| Quick Ratio | 31.54 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.94 |
Financial Efficiency
Return on equity (ROE) is -26.36% and return on invested capital (ROIC) is -18.57%.
| Return on Equity (ROE) | -26.36% |
| Return on Assets (ROA) | -17.95% |
| Return on Invested Capital (ROIC) | -18.57% |
| Return on Capital Employed (ROCE) | -26.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 84 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Disc Medicine has paid $461,000 in taxes.
| Income Tax | 461,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +83.43% in the last 52 weeks. The beta is 2.53, so Disc Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.53 |
| 52-Week Price Change | +83.43% |
| 50-Day Moving Average | 70.11 |
| 200-Day Moving Average | 56.79 |
| Relative Strength Index (RSI) | 63.45 |
| Average Volume (20 Days) | 612,018 |
Short Selling Information
The latest short interest is 2.69 million, so 7.75% of the outstanding shares have been sold short.
| Short Interest | 2.69M |
| Short Previous Month | 2.64M |
| Short % of Shares Out | 7.75% |
| Short % of Float | 9.10% |
| Short Ratio (days to cover) | 6.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -168.76M |
| Pretax Income | -144.93M |
| Net Income | -145.39M |
| EBITDA | -168.64M |
| EBIT | -168.76M |
| Earnings Per Share (EPS) | -$4.53 |
Full Income StatementBalance Sheet
The company has $649.97 million in cash and $30.92 million in debt, giving a net cash position of $619.05 million or $17.81 per share.
| Cash & Cash Equivalents | 649.97M |
| Total Debt | 30.92M |
| Net Cash | 619.05M |
| Net Cash Per Share | $17.81 |
| Equity (Book Value) | 614.17M |
| Book Value Per Share | 17.70 |
| Working Capital | 640.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$134.23 million and capital expenditures -$1.33 million, giving a free cash flow of -$135.56 million.
| Operating Cash Flow | -134.23M |
| Capital Expenditures | -1.33M |
| Free Cash Flow | -135.56M |
| FCF Per Share | -$3.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Disc Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.27% |
| Shareholder Yield | -29.27% |
| Earnings Yield | -4.81% |
| FCF Yield | -4.49% |
Dividend DetailsAnalyst Forecast
The average price target for Disc Medicine is $106.92, which is 23.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $106.92 |
| Price Target Difference | 23.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -36.49% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
